Overview

Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus

Status:
Unknown status

Trial end date:
2018-06-01

Target enrollment:
0

Participant gender:
All

Summary

Oral Lichen Planus (OLP) is an autoimmune, chronic inflammatory mucocutaneous disease characterized by pain and burning sensation. The major types of OLP are the following: reticular, atrophic, erosive-ulcerative, bullous and pigmentous form.Its etiology remains unclear. The presence of auto-cytotoxic T cell clones in the lesions suggests the role of autoimmunity. Numerous treatment options of OLP include topical and systemic agents depending on severity of lesions . Topical corticosteroids abide the mainstay of therapy,and are widely accepted as the primary treatment of choice.Hence this study is designed to evaluate and compare the clinical efficacy of topical Clobetasol 0.05% in orabase and Betamethasone 0.05% in orabase in combination with Clotrimazole 1% in the management of symptomatic Oral Lichen Planus.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Garlapati Komali

Treatments:

Benzocaine
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Clobetasol

Criteria

Inclusion Criteria:

1. Patients with Oral Lichen Planus, who are willing to participate in the study.

2. Patients who are physically healthy and well oriented in time, space and as a person.

3. Patients clinically and histopathologically diagnosed with Oral Lichen Planus.

4. Patients with symptoms i.e. pain and burning sensation due to oral lichen planus.

Exclusion Criteria:

1. Patients with Oral Lichen Planus, who are not willing to participate in the study.

2. Patients with any other mucosal disease or any other skin disease which may be
associated with oral lesions.

3. Patients with a known allergy or contraindication to study medications.

4. Patients with known history of systemic diseases, where steroids are contraindicated.

5. Pregnant women.